To enhance tumor targeting, engineered macrophage EVs conjugated with dibenzocyclooctyne-modified antibodies targeting CD47 and SIRPα via pH-sensitive linkers accumulate selectively within the acidic tumor microenvironment, facilitating tumor cell recognition [265]. The gene discussed is SIRPA; the disease is neoplasm.